biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Forcing Bioasis to Answer

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 16, 2023 4:43pm

98 Views

Post# 35226523

RE:RE:RE:RE:RE:RE:Forcing Bioasis to Answer

So, poof, have you considered the possibility that there are two or more xB3 deals that could be done with Ellipses?

xB3-001 is one, obviously. That one deals with HER2+ but not other HER2 (triple neg, for instance) types of breast cancer and metastases.

The Ellipses/SunRock drug, EP0017, is also a likely candidate for transport across the BBB. It's a fusion protein targeting HER3 (and DR$ and DR%), and it's too big to get itself across the BBB in therapeutic quantities.

Your may be making the case for even more Bioasis business with Ellipses, not less business.

jd

<< Previous

Bullboard Posts

Next >>

Abcourt Mines launches Flordin property drill campaign